Submit a comment

Alterations in Cyclic Adenosine Monophosphate Metabolism in Human Bronchial Asthma. I. LEUKOCYTE RESPONSIVENESS TO β-ADRENERGIC AGENTS
Charles W. Parker, Jay W. Smith
Charles W. Parker, Jay W. Smith
Published January 1, 1973
Citation Information: J Clin Invest. 1973;52(1):48-59. https://doi.org/10.1172/JCI107173.
View: Text | PDF
Research Article

Alterations in Cyclic Adenosine Monophosphate Metabolism in Human Bronchial Asthma. I. LEUKOCYTE RESPONSIVENESS TO β-ADRENERGIC AGENTS

Abstract

In an effort to better define the role of βadrenergic blockade in human bronchial asthma, peripheral blood leukocytes and lymphocytes from individuals with this condition were studied for possible alterations in cyclic AMP metabolism. Using a previously described radioimmunoassay to measure cyclic AMP, cells from asthmatic subjects were shown to have a highly significant decrease in their cyclic AMP response to β-adrenergic agents (isoproterenol, norepinephrine, and epinephrine) by comparison with normal control cells. The alteration in responsiveness was most marked at the time of severe active asthma and returned toward normal during periods of clinical remission. Evidence was presented to indicate that the reduced response in cells from asthmatic individuals was not due to marked alterations in the proportion of T and B lymphocytes. Five normal volunteers were treated with an oral bronchodilator preparation containing theophylline and ephedrine over a 2 wk period without a significant change in the lymphocyte cyclic AMP response.

Authors

Charles W. Parker, Jay W. Smith

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required